Bring your asset to market with focus and full control.
PharmaSync helps asset owners position differentiated science, qualify the right strategic buyers, run confidential outreach, and negotiate structures that protect long-term value across the corridor.
Positioning, buyer mapping, outreach, and term support.
Qualified counterparties, never broad-blast outreach.
Non-confidential teaser, deck, data-room logic, and Q&A file.
Staged gates protect identity, science, and intent.
A credible story for the buyers who should already care.
Asset positioning
We build the strategic narrative around differentiation, evidence, residual risk, and exactly where the asset fits a buyer’s portfolio.
Buyer mapping
We identify strategic and financial counterparties with the mandate, capability, and timing to engage seriously rather than browse.
Process management
We coordinate teasers, NDAs, data-room access, management calls, Q&A, and structured feedback loops end to end.
Term negotiation
We shape structure, economics, retained rights, diligence obligations, governance, and a clear path to signature.
We make the asset easy to understand without flattening the science.
Scientific translation
Dense data becomes buyer-relevant proof points and honest risk disclosures.
Buyer discipline
Outreach is limited to counterparties with a real strategic reason to act.
Process control
Confidentiality, materials, and Q&A cadence are managed deliberately, not reactively.
Term focus
We protect value in the clauses that still matter long after the press release.
Prepare
Validate the data package, sharpen positioning, and set the rules of the process.
Qualify
Map buyers and rank them on fit, capability, timing, and decision authority.
Engage
Run teasers, NDAs, data-room access, Q&A, and structured buyer meetings.
Close
Compare offers, negotiate terms, and drive signature readiness.
Evidence hierarchy
Separate decisive data from supportive but non-critical evidence before buyers see it.
Differentiation
Clarify where the asset wins and where buyers will push back hardest.
Regulatory story
Make agency path, precedent, and open questions explicit and defensible.
CMC story
Frame manufacturing readiness and transfer risk before they become objections.
Market logic
Connect target population, standard of care, and strategic portfolio fit.
Terms range
Set realistic economics and rights packages well before the first offer lands.
China & Asia buyers
Strategic pharma, regional specialty players, and platform companies seeking differentiated rights.
Europe & Gulf capital
Companies and investors able to fund development, manufacturing, and regional launch paths.
US strategic buyers
Portfolio-driven pharma and biotech teams operating against defined therapeutic mandates.
| Structure | When it fits | Pressure points |
|---|---|---|
| Regional license | Owner wants to retain core geography while extending reach. | Territory, field, diligence, supply, and data-sharing rights. |
| Global license | Buyer is best placed to own full development and market path. | Economics, transition, retained rights, and governance. |
| Co-development | Both parties contribute resources or know-how. | Cost share, control, escalation, and future opt-in rights. |
| Option deal | Further evidence is needed before full commitment. | Trigger data, exclusivity, option fee, and exercise mechanics. |
Oncology
Targeted assets and novel modalities.
Immunology
Inflammation and autoimmune programs.
Metabolic
Cardiometabolic and NASH assets.
Cell & Gene
Cell therapy, gene therapy, and enabling platforms.
CNS
Neurodegeneration and psychiatric disorders.
Rare Disease
Orphan and ultra-rare indications.
Devices & Dx
Companion diagnostics and device-led assets.
Digital Health
Trial tech, DTx, and AI-enabled platforms.
Buyer map for platform rights
Segmented strategic buyers by manufacturing capability, clinical appetite, and territory value.
Data-room rebuild
Reorganized a fragmented package into a buyer-ready structure before any outreach.
Partner process reset
Shifted an unfocused process toward buyers with companion diagnostic infrastructure.